CYBERSECURITY-TECH-ACCRD
22.2.2021 12:02:08 CET | Business Wire | Press release
A majority of businesses surveyed for a study by the Economist Intelligence Unit (EIU) and the Cybersecurity Tech Accord released today, see state-led and sponsored cyberattacks as a major threat. They are concerned about catastrophic reputational and financial consequences and call for greater international political cooperation to mitigate these threats.
The survey was conducted between November and December 2020, before the pernicious cyberattack on software company SolarWinds came to light. That attack was a moment of reckoning for many organizations about the challenges posed by state-led and -sponsored cyberattacks but, as the survey reveals, many businesses have long been aware of the escalating threat.
In recent years, cyberattacks led or sponsored by states have transformed cyberspace. This escalating conflict online has been accelerated by the wide-reaching consequences of COVID-19. In fact, almost 8-in-10 respondents say the pandemic has increased the likelihood of a state-led or -sponsored cyberattack on their organization.
Results show private sector leaders expect cyber threats by state actors to increase in the years ahead and want governments to implement effective policy solutions at the national and international level. In further detail, the key study findings are:
- State-led and -sponsored cyberattacks are a source of major concern for private organizations . 80 percent of respondents are concerned about their organization falling victim to a nation-state cyberattack, with the majority saying that this concern has increased in the past five years.
- Companies expect cyber threats from nation-state actors to increase in the next five years and will be second only to that of organized crime. This would be a grave development, given that states have significant resources and advanced tools and technologies, which can later be repurposed by other attackers.
- There is a false sense of security. 68 percent of executives feel their organizations are “very” or “completely” prepared to deal with a cyberattack. Charles Carmakal, senior vice president and chief technology officer at FireEye and one of the experts interviewed by the EIU, suggested that most organizations don’t have tangible experience dealing with such threats because they are rarely the primary targets of these attacks. The recent SolarWinds hack may compel more organizations to think about how they mitigate risk.
- Increased corporate investment in cybersecurity is crucial but government action, nationally and internationally, is needed . 6-in-10 executives say that their country only offers a medium or low level of protection and that stronger international economic and political cooperation is essential to address the challenges, and to cultivate a more secure and stable online environment.
“Recent state-led and -sponsored attacks serve as a powerful reminder of an escalating problem that is too big to ignore,” said Brad Maiorino, executive vice president and chief strategy officer, FireEye. “There needs to be a fundamental shift in security planning beyond the efforts of any one organization, and this shift requires proactive and cooperative action from government and industry.”
“Although cyberattacks are a silent threat, they can have devastating and long-lasting effects on our society. Given the recent escalation of tensions in cyberspace, cooperation between governments is becoming increasingly complicated as political systems differ and technological competition rises,” said Marietje Schaake, president of the CyberPeace Institute. "This survey is an important call to action for democratic governments to step up and think more inclusively about the kind of cyber assistance they provide to protect companies in key sectors, and ultimately civilians."
Since its inception, the Cybersecurity Tech Accord has highlighted this troubling situation, inviting governments to protect the online environment and refrain from using the internet as a domain of conflict, directly or through third parties. As an industry voice and staunch advocate for responsible behavior in cyberspace, the Cybersecurity Tech Accord has consistently called on governments to do more to defend against cyber-threats online, uphold international law, and implement international cybersecurity norms.
“As a coalition of over 150 global technology companies, we are greatly concerned by state-sponsored cyberattacks, which are becoming ever more frequent and sophisticated. Something needs to be done and soon,” said Annalaura Gallo, secretariat of Cybersecurity Tech Accord. “This survey shows that businesses see state-led and -sponsored cyberattacks as a pressing issue that demands governments act nationally and internationally. We need agreement at the United Nations and the involvement of business and civil society through multi-stakeholder forums, such as the Paris Call for Trust and Security in Cyberspace. We hope these survey results will be the start of a larger, global conversation around this important topic.”
The survey targeted over 500 director-level or above executives from businesses in Asia-Pacific, Europe, and the United States, familiar with their organization’s cybersecurity strategy and representing a wide range of industries, led by IT and technology, retail and consumer goods.
For a summary of key takeaways from the report, see the infographic here , and for full details, click here .
To learn more about the Cybersecurity Tech Accord, visit www.cybertechaccord.org .
About the Cybersecurity Tech Accord: In April 2018, 34 global technology and security companies signed the Cybersecurity Tech Accord, a watershed agreement and public commitment to protect and empower civilians online. Since then, this initiative has become the largest industry-led effort of its kind, with over 150 signatory companies across the world pledging to improve the security, stability, and resilience of cyberspace. More information can be found here .
About the Economist Intelligence Unit (EIU): The EIU is the thought leadership, research and analysis division of The Economist Group and the world leader in global business intelligence for executives. The EIU uncovers novel and forward-looking perspectives with access to over 650 expert analysts and editors across 200 countries worldwide. More information can be found here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005178/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
